<?xml version="1.0" encoding="UTF-8"?>
<ref id="B34-pharmaceuticals-13-00303">
 <label>34.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Perillo</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Di Donato</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Pezone</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Di Zazzo</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Giovannelli</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Galasso</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Castoria</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Migliaccio</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>ROS in cancer therapy: The bright side of the moon</article-title>
  <source>Exp. Mol. Med.</source>
  <year>2020</year>
  <volume>52</volume>
  <fpage>192</fpage>
  <lpage>203</lpage>
  <pub-id pub-id-type="doi">10.1038/s12276-020-0384-2</pub-id>
  <pub-id pub-id-type="pmid">32060354</pub-id>
 </element-citation>
</ref>
